EUVIMEDEUVIMED entdecken
Open Access

Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer

Salvador Alonso, Kevan Chu, Elizabeth Granowsky, Valeria Saraiba Rabanales, Marie J Parsons, Himari Gunasinghe, Jinru Shia, Rona Yaeger, Lukas E Dow

Cancer Cell · 2026-07 · 44 (7) · 1368-1380.e8

DOI: 10.1016/j.ccell.2026.04.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2026-07. Verfasst von Salvador Alonso und 8 weiteren Autor:innen. Beteiligte Einrichtung: Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA; Department of Gastrointestinal Medical Oncology, Division of Cancer…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Colorectal Neoplasms, Drug Resistance, Neoplasm, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute Division of Cancer Epidemiology and Genetics, Burroughs Wellcome Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KRAS is mutationally activated in 45%-50% of colorectal cancer (CRC) cases, and while KRAS-targeted therapies have shown clinical promise, drug resistance limits their efficacy. To explore the mechanisms underlying KRAS inhibitor resistance, we use targeted exome sequencing and spatial transcriptomics on patient-matched CRC biopsies following combined treatment with KRASG12C and EGFR inhibitors. We show that acquired genetic events are identified in most patients at progression but are often subclonal and coexist with transcriptional adaptive states. Mesenchymal, YAP, and fetal-like transcriptional signatures predominate in resistant tumors, while inflammatory programs are induced early on treatment. Single-cell spatial analysis reveals intratumoral heterogeneity, with diverse adaptive states in different zones of individual tumors. Using human and murine organoid models, we show that drug-induced inflammatory programs are, at least in part, cancer-cell autonomous, and precede the emergence of drug resistance. We identify TBK1 as a target to abrogate the inflammatory adaptive phase and enhance responses to KRAS inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsColorectal NeoplasmsDrug Resistance, NeoplasmProto-Oncogene Proteins p21(ras)AnimalsFemaleHumansMiceAcetonitrilesErbB ReceptorsExosomesHEK293 CellsMutationOrganoidsPiperazinesProtein Kinase InhibitorsProtein Serine-Threonine KinasesPyridinesPyrimidinesSingle-Cell AnalysisSpatial Transcriptomics

Stichwörter der Autor:innen

CRCKRASTBK1inflammationplasticity

Substanzen

AcetonitrilesadagrasibAntineoplastic AgentsErbB ReceptorsKRAS protein, humanPiperazinesProtein Kinase InhibitorsProtein Serine-Threonine KinasesProto-Oncogene Proteins p21(ras)Pyridines

Autor:innen und Institutionen

  • Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA; Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA. Electronic add…
  • Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA; Weill Cornell Graduate School and Medical Sciences, Weill Cornell Medicine, New York, NY, USA.
  • Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
  • Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Förderung

  • NCI NIH HHS
  • National Cancer Institute Division of Cancer Epidemiology and Genetics
  • Burroughs Wellcome Fund
  • Conquer Cancer Foundation
  • Emerald Foundation
  • National Cancer Institute
  • The Starr Foundation
  • Starr Cancer Consortium

Zitieren

APA

Alonso, S., Chu, K., Granowsky, E., Rabanales, V. S., Parsons, M. J., Gunasinghe, H., Shia, J., Yaeger, R., & Dow, L. E. (2026). Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer. Cancer Cell, 44(7), 1368-1380.e8. https://doi.org/10.1016/j.ccell.2026.04.009

Vancouver

Alonso S, Chu K, Granowsky E, Rabanales VS, Parsons MJ, Gunasinghe H, et al. Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer. Cancer Cell. 2026;44(7):1368-1380.e8. doi:10.1016/j.ccell.2026.04.009

BibTeX
@article{Alonso2026,
  author = {Alonso, Salvador and Chu, Kevan and Granowsky, Elizabeth and Rabanales, Valeria Saraiba and Parsons, Marie J and Gunasinghe, Himari and Shia, Jinru and Yaeger, Rona and Dow, Lukas E},
  title = {Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer},
  journal = {Cancer Cell},
  year = {2026},
  volume = {44},
  number = {7},
  pages = {1368--1380.e8},
  doi = {10.1016/j.ccell.2026.04.009}
}
Kostenlos starten →